Clinical trial
A Randomized, Double-blind, Phase I Study Comparing the Pharmacokinetic and Safety of SIBP-04 and Bevacizumab in Healthy Male Subjects
NCT04135898 is registered in ClinicalTrials.gov with Shanghai Institute Of Biological Products as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Phase I Study Comparing the Pharmacokinetic and Safety of SIBP-04 and Bevacizumab in Healthy Male Subjects
- Lead sponsor
- Shanghai Institute Of Biological Products
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 23, 2019
- Completion date
- March 16, 2020
- Enrollment
- 88 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy male